The Limited Times

Now you can see non-English news...

After death: EMA is now also examining connection with blood clots at Johnson & Johnson

2021-04-10T04:35:36.188Z


Four cases of blood clots after a corona vaccination with Johnson & Johnson are currently being investigated by the EU Medicines Agency. One person died.


Four cases of blood clots after a corona vaccination with Johnson & Johnson are currently being investigated by the EU Medicines Agency.

One person died.

Amsterdam - After there had been several thrombosis cases after vaccinations at Astrazeneca *, the EU Medicines Agency (EMA) is now also examining a connection between the vaccine from the US manufacturer Johnson & Johnson * and blood clots.

 Johnson & Johnson: EMA examines next corona vaccine for connection with blood clots after death

The reason are reports of four cases of thrombosis after vaccination with the vaccine from the US manufacturer Johnson & Johnson.

As the EMA announced on Friday, three cases of thrombosis were reported in the US and another as part of a clinical study at an unspecified location.

One of the cases was therefore fatal.

Meanwhile, the Sankt Elisabeth Hospital in Gütersloh is registering an increasing number of patients who suffer from headaches and are now afraid of a brain thrombosis, as reported by owl24.de *

The agency emphasized that a connection with the US manufacturer's vaccine had not yet been established.

The frequency of reported incidents with blood clots in the brain is approximately 1 in 100,000, according to the EMA.

The EMA continued to give the unreserved green light for use.

The drug authority explained that the benefits of the active ingredient should be rated higher than the risks.

Johnson & Johnson: no vaccination in Germany yet - but 10 million doses ordered

Johnson & Johnson's vaccine was approved in the European Union in early March.

It is the fourth vaccine against Covid-19, after the vaccines from Biontech / Pfizer, Moderna and Astrazeneca

have received the EMA Go.

The American pharmaceutical company based in New Jersey * does not yet play a role in the German vaccination strategy.

According to the Ministry of Health * from March 22nd, Germany expects around 10 million vaccine doses from Johnson & Johnson in the current second quarter.

From April 19, Johnson & Johnson should actually be vaccinated in the EU.

To date, immunization in Germany has only been carried out with Biontech / Pfizer, Moderna and Astrazeneca.

By April 9, 11,453,405 people in Germany had received at least one injection.

With 11,453,405 vaccinations, Biontech / Pfizer has the largest share, Astrazeneca was used in 3,412,673 people, Moderna in 669,335.

Johnson & Johnson: What makes the vector vaccine different from other vaccines?

The three established vaccines require a second vaccination for optimal protection.

With the Johnson & Johnson vector vaccine, however, one vaccine dose is sufficient.

At this point in time, however, it is not possible to assess whether a so-called booster vaccination will be necessary later, as long-term data are not yet available.

According to initial scientific findings, the effectiveness of the vaccine is more than sufficient, but less than that of the known mRNA vaccines.

One of the benefits of Johnson & Johnson is storage.

As with the Astrazeneca vector vaccine, it can be stored in the refrigerator for months.

General practitioners in particular should benefit from this, since they do not have to worry - as with other vaccines - that the vaccine has to be disposed of without being injected for logistical reasons.

(as / md / afp) * Merkur.de and owl24.de are an offer from IPPEN.MEDIA

Source: merkur

All news articles on 2021-04-10

You may like

Life/Entertain 2024-01-30T10:39:08.085Z
Life/Entertain 2024-01-31T09:11:06.735Z

Trends 24h

News/Politics 2024-03-27T16:45:54.081Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.